Background: Candidiasis is a serious life-threatening infection that is associated with significant morbidity and mortality rates. The incidence of this infection has increased in recent years, especially among immunocompromised patients. Methods: The in vitro activities of two novel azole compounds (aryl-1,2,4-triazol- 3-ylthio analogues of fluconazole [ATTAFs]) and five comparator antifungal agents against 52 clinical Candida isolates from 5 different species were determined. Results: The novel azole compounds had the lowest geometric mean MICs, followed by fluconazole. Moreover, combinations of these compounds with fluconazole exhibited synergistic effects against fluconazole-susceptible (22 of 23 isolates), fluconazole-susceptible dose-dependent (10 of 13 isolates), and fluconazole-resistant (1 of 16 isolates) Candida isolates.Conclusions: Although ATTAF-1 and ATTAF-2 exhibited potent activities against clinical Candida isolates, their effectiveness, alone or in combination with fluconazole, for the treatment of Candida infections needs to be determined; in addition, the underlying mechanisms of action should be investigated.
Full conference title:
- ASM Microbe 2nd (2017)